Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 12.08.2019 | 09:34

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Announcement pursuant to Art. 5 para. 1 lit. b), para. 3 of Regulation (EU) No 596/2014 and Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052

12.08.2019 / 09:34
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


- Share buy-back - 8th Interim Report

In the period from August 5, 2019 until and including August 9, 2019, a total of 99,453 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care') announced on June 14, 2019 pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.

The purchase was carried out exclusively by a credit institution commissioned by Fresenius Medical Care via the XETRA trading platform on the Frankfurt Stock Exchange:

Day of repurchase Aggregated volume in number of shares Weighted average share price
in EUR
05/08/2019 - -
06/08/2019 20,000 60.3018
07/08/2019 19,453 59.7928
08/08/2019 60,000 60.2285
09/08/2019 - -
 

The total volume of shares repurchased within the framework of this share buy-back in the period from June 17, 2019 until and including August 9, 2019 therefore amounts to 1,633,780 shares.

Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors.

Fresenius Medical Care AG & Co. KGaA
represented by Fresenius Medical Care Management AG
represented by its Management Board

Bad Homburg v.d.H., August 12, 2019



12.08.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
<

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2019

21. Februar 2020, 11:54

Aktuelle Research-Studie

Media and Games Invest plc

Original-Research: Media and Games Invest plc (von First Berlin Equity Research GmbH): BUY

21. Februar 2020